Pharmaceutical - Mergers & Acquisitions, Roche


Popular Filters

Roche partners in new company for MS research

Roche partners in new company for MS research


Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

Roche to acquire Genia Technologies for up to $350 million

Roche to acquire Genia Technologies for up to $350 million


Swiss drug major Roche said this morning that it plans to acquire Genia Technologies, a privately held…

Genia TechnologiesMergers & AcquisitionsPharmaceuticalRoche

Report: Life science companies experience IPO slowdown


Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Amylin said to be attracting several Big Pharma suitors


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ratchets up the pressure on Illumina; analytical view


If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets,…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche presses on with takeover, despite further rejection by Illumina board


Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis


There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid


Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche has options beyond Illumina


Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said:…

FinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche extends Illumina takeover deadline


Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina…

HomeIlluminaMergers & AcquisitionsPharmaceuticalRoche

Riemser strengthens oncology range with Roche drug


German drugmaker Riemser Arzneimittel AG is extending its range of supportive cancer therapy products…

Mergers & AcquisitionsOncologyOstacPharmaceuticalRiemser ArztneimittelRoche

Illumina board says Roche hostile bid “grossly inadequate”


Having thoroughly reviewed Swiss drug and diagnostics major Roche’s (ROG: SIX) hostile takeover…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina implements “poison pill” with regard to Roche bid


Responding to Swiss drug major Roche’s (ROG: SIX) hostile takeover over offer of $44.50 per share…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche makes $5.7 billion hostile bid for Illumina


Swiss drugs and diagnostic major Roche (ROG: SIX) announced this morning that it is proposing to acquire…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche in epigenetics drug discovery collaboration


USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

Roche acquires Verum Diagnostica for 11 million euros


Swiss drugs and diagnostics major Roche (ROG: SIX) has signed an agreement under which it will acquire…

Mergers & AcquisitionsPharmaceuticalRocheVerum Diagnostica

Arrowhead acquires RNA assets and site from Roche, which takes minority stake in the firm


California, USA-based Arrowhead Research Corp Nasdaq: ARWR) said yesterday that it has acquired RNA therapeutics…

Arrowhead ResearchFinancialMergers & AcquisitionsPharmaceuticalRoche

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma


In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

Company Spotlight



Back to top